HC Wainwright Issues Negative Estimate for IN8bio Earnings

IN8bio, Inc. (NASDAQ:INAB) – Investment analysts at HC Wainwright lowered their Q2 2025 earnings estimates for IN8bio in a research note issued on Thursday, May 8th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.04). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s FY2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.19) EPS.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01).

IN8bio Stock Up 3.6%

INAB stock opened at $0.16 on Monday. The company’s 50 day simple moving average is $0.19 and its 200-day simple moving average is $0.26. The firm has a market capitalization of $14.80 million, a PE ratio of -0.22 and a beta of 0.23. IN8bio has a 12 month low of $0.13 and a 12 month high of $1.74. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84.

Institutional Trading of IN8bio

Large investors have recently modified their holdings of the business. Jane Street Group LLC grew its position in shares of IN8bio by 296.7% in the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after purchasing an additional 86,696 shares during the period. Geode Capital Management LLC grew its position in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares during the period. Sigma Planning Corp grew its position in shares of IN8bio by 22.3% in the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares during the period. AIGH Capital Management LLC boosted its holdings in IN8bio by 269.7% in the fourth quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock valued at $1,593,000 after acquiring an additional 4,517,227 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in IN8bio by 1,064.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock valued at $1,302,000 after acquiring an additional 4,628,482 shares during the last quarter. 92.05% of the stock is currently owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.